Lucerastat Phase 3 Trial Fully Enrolled, Results Likely Late in Year

Lucerastat Phase 3 Trial Fully Enrolled, Results Likely Late in Year

293330

Lucerastat Phase 3 Trial Fully Enrolled, Results Likely Late in Year

A Phase 3 trial evaluating lucerastat, an investigational substrate reduction therapy for Fabry disease, is fully enrolled and underway in 118 adult patients. Results from the MODIFY trial (NCT03425539) are expected toward the end of this year. Those who complete the trial will be invited to continue or start treatment with oral lucerastat in an open-label extension study scheduled to run for about two years. “This first quarter of 2021 is loaded with important progress…

You must be logged in to read/download the full post.